Advances in Approaches to Managing Esophageal Adenocarcinoma.

Authors

Fabian Nimczewski, Sjaak Pouwels, Jens Hoeppner

Published in

Annual review of medicine. Jul 27, 2026. Epub Jul 27, 2026.

Abstract

Management of esophageal adenocarcinoma is moving toward personalized, multimodal approaches, with perioperative immunotherapy now a key component. Shortly before 2025, perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy was established as superior to neoadjuvant chemoradiotherapy, significantly improving overall survival by better controlling micrometastatic disease. Recent US Food and Drug Administration and European Medical Agency approvals of perioperative durvalumab adds immunotherapy to FLOT. Organ-preserving "watch-and-wait" strategies are gaining momentum for clinical complete responders to avoid surgery-related morbidity. We highlight landmark studies that inform use of different modern multimodal approaches. These advances, combined with robot-assisted surgery, are collectively improving 5-year survival for localized disease.

PMID:
42507831
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.